Related Experiment Videos
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
S Hetherington1, S McGuirk, G Powell
1HIV/OI Clinical Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA. svh31379@glaxowellcome
Clinical Therapeutics
|December 1, 2001
Summary
Hypersensitivity to abacavir sulfate is an idiosyncratic reaction affecting about 5% of patients, presenting with systemic symptoms like fever and rash. Immediate discontinuation is crucial upon symptom onset, as abacavir is contraindicated for future use.
Area of Science:
- Pharmacology and Toxicology
- Clinical Medicine
- Drug Safety
Background:
- Hypersensitivity reactions are diverse clinical responses to various chemical compounds.
- Abacavir sulfate is a nucleoside reverse transcriptase inhibitor used in treating viral infections.
Purpose of the Study:
- To characterize the clinical presentation of hypersensitivity reactions to abacavir sulfate.
- To determine the incidence and key features of abacavir-induced hypersensitivity.
Main Methods:
- Retrospective review of adverse event data from approximately 200,000 patients exposed to abacavir.
- Classification of hypersensitivity cases as definitive or probable based on symptom resolution and reintroduction response.
Main Results:
- Identified 1803 hypersensitivity cases; 4.3% incidence in clinical trials/expanded access programs.
- Common symptoms include fever, rash, malaise, gastrointestinal issues, and respiratory problems.
- Reactions typically occurred within 6 weeks; rechallenge led to rapid symptom recurrence, sometimes with hypotension.
Conclusions:
- Hypersensitivity to abacavir is an idiosyncratic, systemic syndrome, often treatment-limiting.
- Immediate abacavir discontinuation is essential upon suspected hypersensitivity.
- Prior hypersensitivity to abacavir is an absolute contraindication for future use of any abacavir-containing formulation.